Eli Lilly And Company ((LLY)), AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company, in collaboration with AstraZeneca, is conducting a Phase 3 clinical study titled ‘A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer – SUNRAY-02’. The study aims to evaluate the effectiveness of olomorasib combined with standard immunotherapies in treating KRAS G12C-mutant non-small cell lung cancer (NSCLC), a significant step in advancing cancer treatment options.
The interventions being tested include the drug olomorasib, administered orally, in combination with pembrolizumab or durvalumab, both administered intravenously. These combinations are compared against standard treatments involving a placebo, with the goal of improving outcomes for patients with resected or unresectable NSCLC.
The study follows a randomized, double-blind, placebo-controlled design with a parallel intervention model. Participants and investigators are masked to the treatment allocations, ensuring unbiased results. The primary purpose of the study is treatment-focused, aiming to establish the efficacy of the new drug combinations.
The study began on March 27, 2025, with recruitment currently ongoing. The last update was submitted on July 22, 2025. These dates are crucial for tracking the study’s progress and anticipating future developments.
This clinical update could influence the stock performance of Eli Lilly and AstraZeneca, as successful outcomes may enhance their market positions in the oncology sector. Investors should monitor the study’s progress, as positive results could shift market dynamics, especially in the competitive field of cancer treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.